Cargando…

NLR and BRCA mutational status in patients with high grade serous advanced ovarian cancer

Laboratory-markers of the systemic inflammatory-response, such as neutrophil/lymphocyte-ratio (NLR) have been studied as prognostic factors in several tumors but in OC-patients their role is still controversial and no data about the possible correlation with the BRCA-status has been ever reported. W...

Descripción completa

Detalles Bibliográficos
Autores principales: Marchetti, Claudia, D’Indinosante, Marco, Bottoni, Carolina, Di Ilio, Chiara, Di Berardino, Stefano, Costantini, Barbara, Minucci, Angelo, Vertechy, Laura, Scambia, Giovanni, Fagotti, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8159985/
https://www.ncbi.nlm.nih.gov/pubmed/34045513
http://dx.doi.org/10.1038/s41598-021-90361-w
_version_ 1783700188346449920
author Marchetti, Claudia
D’Indinosante, Marco
Bottoni, Carolina
Di Ilio, Chiara
Di Berardino, Stefano
Costantini, Barbara
Minucci, Angelo
Vertechy, Laura
Scambia, Giovanni
Fagotti, Anna
author_facet Marchetti, Claudia
D’Indinosante, Marco
Bottoni, Carolina
Di Ilio, Chiara
Di Berardino, Stefano
Costantini, Barbara
Minucci, Angelo
Vertechy, Laura
Scambia, Giovanni
Fagotti, Anna
author_sort Marchetti, Claudia
collection PubMed
description Laboratory-markers of the systemic inflammatory-response, such as neutrophil/lymphocyte-ratio (NLR) have been studied as prognostic factors in several tumors but in OC-patients their role is still controversial and no data about the possible correlation with the BRCA-status has been ever reported. We consecutively enrolled a series of 397 newly diagnosed high-grade serous-advanced OC-patients. All patients were tested for BRCA-mutational-status and blood-parameters have been collected 48 h before staging-surgery. A significant correlation of NLR with disease distribution (p < 0.005) was found and patients with NLR < 4 underwent primary-debulking-surgery more frequently (p-value 0.001), with a lower surgical-complexity-score (p-value 0.002). Regarding survival-data, patients with NLR < 4 had a significant 7-month increase in mPFS (26 vs 19 months, p = 0.009); focusing on the BRCA-status, among both BRCA-mutated and BRCA-wild type patients, those with lower NLR had a significantly prolonged mPFS compared to patients with NLR > 4 (BRCA-mutated: 35 vs 23 months, p = 0.03; BRCA-wt: 19 vs 16 months, p = 0.05). At multivariate-analysis, independent factors of prolonged PFS were BRCA mutational status, having received complete cytoreduction and NLR < 4. Also, the strongest predictors of longer OS were BRCA-mutational status, having received complete cytoreductive surgery, NLR < 4 and age. NLR is confirmed to be a prognostic marker in OC-patients and it seems unrelated with BRCA-mutational status.
format Online
Article
Text
id pubmed-8159985
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-81599852021-05-28 NLR and BRCA mutational status in patients with high grade serous advanced ovarian cancer Marchetti, Claudia D’Indinosante, Marco Bottoni, Carolina Di Ilio, Chiara Di Berardino, Stefano Costantini, Barbara Minucci, Angelo Vertechy, Laura Scambia, Giovanni Fagotti, Anna Sci Rep Article Laboratory-markers of the systemic inflammatory-response, such as neutrophil/lymphocyte-ratio (NLR) have been studied as prognostic factors in several tumors but in OC-patients their role is still controversial and no data about the possible correlation with the BRCA-status has been ever reported. We consecutively enrolled a series of 397 newly diagnosed high-grade serous-advanced OC-patients. All patients were tested for BRCA-mutational-status and blood-parameters have been collected 48 h before staging-surgery. A significant correlation of NLR with disease distribution (p < 0.005) was found and patients with NLR < 4 underwent primary-debulking-surgery more frequently (p-value 0.001), with a lower surgical-complexity-score (p-value 0.002). Regarding survival-data, patients with NLR < 4 had a significant 7-month increase in mPFS (26 vs 19 months, p = 0.009); focusing on the BRCA-status, among both BRCA-mutated and BRCA-wild type patients, those with lower NLR had a significantly prolonged mPFS compared to patients with NLR > 4 (BRCA-mutated: 35 vs 23 months, p = 0.03; BRCA-wt: 19 vs 16 months, p = 0.05). At multivariate-analysis, independent factors of prolonged PFS were BRCA mutational status, having received complete cytoreduction and NLR < 4. Also, the strongest predictors of longer OS were BRCA-mutational status, having received complete cytoreductive surgery, NLR < 4 and age. NLR is confirmed to be a prognostic marker in OC-patients and it seems unrelated with BRCA-mutational status. Nature Publishing Group UK 2021-05-27 /pmc/articles/PMC8159985/ /pubmed/34045513 http://dx.doi.org/10.1038/s41598-021-90361-w Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Marchetti, Claudia
D’Indinosante, Marco
Bottoni, Carolina
Di Ilio, Chiara
Di Berardino, Stefano
Costantini, Barbara
Minucci, Angelo
Vertechy, Laura
Scambia, Giovanni
Fagotti, Anna
NLR and BRCA mutational status in patients with high grade serous advanced ovarian cancer
title NLR and BRCA mutational status in patients with high grade serous advanced ovarian cancer
title_full NLR and BRCA mutational status in patients with high grade serous advanced ovarian cancer
title_fullStr NLR and BRCA mutational status in patients with high grade serous advanced ovarian cancer
title_full_unstemmed NLR and BRCA mutational status in patients with high grade serous advanced ovarian cancer
title_short NLR and BRCA mutational status in patients with high grade serous advanced ovarian cancer
title_sort nlr and brca mutational status in patients with high grade serous advanced ovarian cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8159985/
https://www.ncbi.nlm.nih.gov/pubmed/34045513
http://dx.doi.org/10.1038/s41598-021-90361-w
work_keys_str_mv AT marchetticlaudia nlrandbrcamutationalstatusinpatientswithhighgradeserousadvancedovariancancer
AT dindinosantemarco nlrandbrcamutationalstatusinpatientswithhighgradeserousadvancedovariancancer
AT bottonicarolina nlrandbrcamutationalstatusinpatientswithhighgradeserousadvancedovariancancer
AT diiliochiara nlrandbrcamutationalstatusinpatientswithhighgradeserousadvancedovariancancer
AT diberardinostefano nlrandbrcamutationalstatusinpatientswithhighgradeserousadvancedovariancancer
AT costantinibarbara nlrandbrcamutationalstatusinpatientswithhighgradeserousadvancedovariancancer
AT minucciangelo nlrandbrcamutationalstatusinpatientswithhighgradeserousadvancedovariancancer
AT vertechylaura nlrandbrcamutationalstatusinpatientswithhighgradeserousadvancedovariancancer
AT scambiagiovanni nlrandbrcamutationalstatusinpatientswithhighgradeserousadvancedovariancancer
AT fagottianna nlrandbrcamutationalstatusinpatientswithhighgradeserousadvancedovariancancer